Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Down 4.3 %

Shares of CARA opened at $5.15 on Friday. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $11.39. The stock has a market cap of $23.56 million, a PE ratio of -0.25 and a beta of 0.50. The business’s 50-day moving average price is $5.07 and its 200-day moving average price is $4.24.

Institutional Trading of Cara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its stake in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in Cara Therapeutics during the 4th quarter valued at about $953,000. XTX Topco Ltd bought a new position in Cara Therapeutics during the 3rd quarter valued at approximately $29,000. Shay Capital LLC purchased a new stake in Cara Therapeutics in the 4th quarter worth approximately $524,000. Finally, Curi RMB Capital LLC bought a new stake in shares of Cara Therapeutics in the 4th quarter worth approximately $277,000. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.